Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.

Cox MC, Castiello L, Mattei M, Santodonato L, D'Agostino G, Muraro E, Martorelli D, Lapenta C, Di Napoli A, Di Landro F, Cangemi M, Pavan A, Castaldo P, Hohaus S, Donati S, Montefiore E, Berdini C, Carlei D, Monque DM, Ruco L, Prosperi D, Tafuri A, Spadaro F, Sestili P, Spada M, Dolcetti R, Santini SM, Rozera C, Aricò E, Capone I, Belardelli F.

Clin Cancer Res. 2019 Sep 1;25(17):5231-5241. doi: 10.1158/1078-0432.CCR-19-0709. Epub 2019 Jun 6.

PMID:
31171545
2.

Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.

Ramayanti O, Verkuijlen SAWM, Novianti P, Scheepbouwer C, Misovic B, Koppers-Lalic D, van Weering J, Beckers L, Adham M, Martorelli D, Middeldorp JM, Pegtel DM.

Int J Cancer. 2019 May 15;144(10):2555-2566. doi: 10.1002/ijc.31967. Epub 2018 Dec 6.

3.

Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer.

Muraro E, Furlan C, Avanzo M, Martorelli D, Comaro E, Rizzo A, Fae' DA, Berretta M, Militello L, Del Conte A, Spazzapan S, Dolcetti R, Trovo' M.

Front Immunol. 2017 Nov 6;8:1476. doi: 10.3389/fimmu.2017.01476. eCollection 2017.

4.

Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.

Montico B, Lapenta C, Ravo M, Martorelli D, Muraro E, Zeng B, Comaro E, Spada M, Donati S, Santini SM, Tarallo R, Giurato G, Rizzo F, Weisz A, Belardelli F, Dolcetti R, Dal Col J.

Oncoimmunology. 2017 Jul 31;6(11):e1356964. doi: 10.1080/2162402X.2017.1356964. eCollection 2017.

5.

Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.

Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, Alongi F, Del Conte A, Militello L, Muraro E, Martorelli D, Spazzapan S, Berretta M.

Radiother Oncol. 2018 Jan;126(1):177-180. doi: 10.1016/j.radonc.2017.08.032. Epub 2017 Sep 21.

PMID:
28943046
6.

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A.

Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22.

PMID:
28935990
7.

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.

Turrini R, Merlo A, Martorelli D, Faè DA, Sommaggio R, Montagner IM, Barbieri V, Marin O, Zanovello P, Dolcetti R, Rosato A.

Oncoimmunology. 2017 Mar 16;6(4):e1304338. doi: 10.1080/2162402X.2017.1304338. eCollection 2017.

8.

Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells.

Muraro E, Merlo A, Martorelli D, Cangemi M, Dalla Santa S, Dolcetti R, Rosato A.

Front Immunol. 2017 Feb 27;8:197. doi: 10.3389/fimmu.2017.00197. eCollection 2017. Review.

9.

In-depth analysis of compartmentalization of HIV-1 matrix protein p17 in PBMC and plasma.

Selleri M, Dolcetti R, Caccuri F, Giombini E, Rozera G, Abbate I, Mammone A, Zanussi S, Martorelli D, Fiorentini S, Caruso A, Capobianchi MR.

New Microbiol. 2017 Jan;40(1):58-61. Epub 2017 Jan 9.

10.

Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy.

Faè DA, Martorelli D, Mastorci K, Muraro E, Dal Col J, Franchin G, Barzan L, Comaro E, Vaccher E, Rosato A, Dolcetti R.

Cancer Immunol Res. 2016 May;4(5):431-40. doi: 10.1158/2326-6066.CIR-15-0108. Epub 2016 Mar 23.

11.

Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay.

Nawaz I, Moumad K, Martorelli D, Ennaji MM, Zhou X, Zhang Z, Dolcetti R, Khyatti M, Ernberg I, Hu LF.

Clin Epigenetics. 2015 Aug 22;7:89. doi: 10.1186/s13148-015-0119-8. eCollection 2015.

12.

Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.

Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalone S, Militello L, Lombardi D, Spazzapan S, Perin T, Massarut S, Crivellari D, Dolcetti R, Martorelli D.

J Transl Med. 2015 Jun 27;13:204. doi: 10.1186/s12967-015-0567-0.

13.

A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.

Martorelli D, Muraro E, Mastorci K, Dal Col J, Faè DA, Furlan C, Giagulli C, Caccuri F, Rusnati M, Fiorentini S, Carbone A, Caruso A, Dolcetti R.

Int J Cancer. 2015 Sep 15;137(6):1374-85. doi: 10.1002/ijc.29494. Epub 2015 Mar 9.

14.

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.

Miolo G, Muraro E, Martorelli D, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Viel E, Comaro E, Talamini R, Bidoli E, Turchet E, Crivellari D, Dolcetti R.

BMC Cancer. 2014 Dec 15;14:954. doi: 10.1186/1471-2407-14-954.

15.

A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity.

Giagulli C, Caccuri F, Cignarella F, Lougaris V, Martorelli D, Bugatti A, Rusnati M, Dolcetti R, Vitali M, Plebani A, Fiorentini S, Caruso A.

AIDS. 2014 Oct 23;28(16):2355-64. doi: 10.1097/QAD.0000000000000423.

PMID:
25121556
16.

Detection of HIV-1 matrix protein p17 quasispecies variants in plasma of chronic HIV-1-infected patients by ultra-deep pyrosequencing.

Giombini E, Dolcetti R, Caccuri F, Selleri M, Rozera G, Abbate I, Bartolini B, Martorelli D, Faè DA, Fiorentini S, Giagulli C, Capobianchi MR, Caruso A.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):332-9. doi: 10.1097/QAI.0000000000000164.

PMID:
24732873
17.

Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth.

Caccuri F, Giagulli C, Reichelt J, Martorelli D, Marsico S, Bugatti A, Barone I, Rusnati M, Guzman CA, Dolcetti R, Caruso A.

J Virol. 2014 May;88(10):5706-17. doi: 10.1128/JVI.03142-13. Epub 2014 Mar 12.

18.

Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas.

Dolcetti R, Dal Col J, Martorelli D, Carbone A, Klein E.

Semin Cancer Biol. 2013 Dec;23(6):441-56. doi: 10.1016/j.semcancer.2013.07.005. Epub 2013 Aug 3. Review.

PMID:
23917255
19.

Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.

Muraro E, Martorelli D, Dolcetti R.

Hum Vaccin Immunother. 2013 May;9(5):1078-83. doi: 10.4161/hv.23970. Epub 2013 Feb 13. Review.

20.

Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto's thyroiditis.

Caselli E, Zatelli MC, Rizzo R, Benedetti S, Martorelli D, Trasforini G, Cassai E, degli Uberti EC, Di Luca D, Dolcetti R.

PLoS Pathog. 2012;8(10):e1002951. doi: 10.1371/journal.ppat.1002951. Epub 2012 Oct 4.

21.

IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas.

Martorelli D, Guidoboni M, De Re V, Muraro E, Turrini R, Merlo A, Pasini E, Caggiari L, Romagnoli L, Spina M, Mortarini R, Gasparotto D, Mazzucato M, Carbone A, Rosato A, Anichini A, Dolcetti R.

Clin Cancer Res. 2012 Aug 1;18(15):4080-91. doi: 10.1158/1078-0432.CCR-12-0763. Epub 2012 Jun 15.

22.

Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Martorelli D, Muraro E, Merlo A, Turrini R, Faè DA, Rosato A, Dolcetti R.

Clin Dev Immunol. 2012;2012:931952. doi: 10.1155/2012/931952. Epub 2012 Jan 29. Review.

23.

Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets.

Dal Col J, Mastorci K, Faè DA, Muraro E, Martorelli D, Inghirami G, Dolcetti R.

Cancer Res. 2012 Apr 1;72(7):1825-35. doi: 10.1158/0008-5472.CAN-11-2505. Epub 2012 Feb 6.

24.

A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.

Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, Talamini R, Mastorci K, Lombardi D, Perin T, Carbone A, Veronesi A, Crivellari D, Dolcetti R.

Breast Cancer Res. 2011;13(6):R117. doi: 10.1186/bcr3060.

25.

Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells.

Martorelli D, Coppotelli G, Muraro E, Dolcetti R, Masucci MG.

Cancer Immunol Immunother. 2012 Jun;61(6):881-92. doi: 10.1007/s00262-011-1157-5. Epub 2011 Nov 17.

PMID:
22089857
26.

Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives.

Cecco S, Muraro E, Giacomin E, Martorelli D, Lazzarini R, Baldo P, Dolcetti R.

Curr Cancer Drug Targets. 2011 Jan;11(1):85-102. Review.

PMID:
21062241
27.

Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer.

Martorelli D, Muraro E, Merlo A, Turrini R, Rosato A, Dolcetti R.

Int Rev Immunol. 2010 Aug;29(4):371-402. doi: 10.3109/08830185.2010.489658. Review.

PMID:
20635880
28.

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders.

Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, Rosato A.

Haematologica. 2010 Oct;95(10):1769-77. doi: 10.3324/haematol.2010.023689. Epub 2010 Apr 26. Review.

29.

Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders.

Buonaguro L, Petrizzo A, Tornesello M, Napolitano M, Martorelli D, Castello G, Beneduce G, De Renzo A, Perrella O, Romagnoli L, Sousa V, De Re V, Dolcetti R, Buonaguro FM.

J Transl Med. 2010 Feb 19;8:18. doi: 10.1186/1479-5876-8-18.

30.

Undifferentiated nasopharyngeal carcinoma from a nonendemic area: protective role of HLA allele products presenting conserved EBV epitopes.

Pasini E, Caggiari L, Dal Maso L, Martorelli D, Guidoboni M, Vaccher E, Barzan L, Franchin G, Gloghini A, De Re V, Sacchi N, Serraino D, Carbone A, Rosato A, Dolcetti R.

Int J Cancer. 2009 Sep 15;125(6):1358-64. doi: 10.1002/ijc.24515.

31.

Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds.

Montrone M, Martorelli D, Rosato A, Dolcetti R.

Endocr Metab Immune Disord Drug Targets. 2009 Jun;9(2):113-31. Review.

PMID:
19519462
32.

Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy.

Martorelli D, Houali K, Caggiari L, Vaccher E, Barzan L, Franchin G, Gloghini A, Pavan A, Da Ponte A, Tedeschi RM, De Re V, Carbone A, Ooka T, De Paoli P, Dolcetti R.

Int J Cancer. 2008 Sep 1;123(5):1100-7. doi: 10.1002/ijc.23621.

33.

High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance.

Caggiari L, Guidoboni M, Vaccher E, Barzan L, Franchin G, Gloghini A, Martorelli D, Zancai P, Bortolin MT, Mazzucato M, Serraino D, Carbone A, De Paoli P, Dolcetti R.

Infect Agent Cancer. 2007 Mar 1;2:5.

34.

Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.

Tedeschi R, Pin E, Martorelli D, Bidoli E, Marus A, Pratesi C, Bortolin MT, Zanussi S, Vaccher E, Dolcetti R, De Paoli P.

Clin Vaccine Immunol. 2007 Apr;14(4):435-41. Epub 2007 Feb 28.

Supplemental Content

Loading ...
Support Center